Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease

Christian Torp-Pedersen; A John Camm; Noam N Butterfield; Garth Dickinson; Gregory N Beatch

doi:10.1016/j.ijcard.2011.10.108

Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease

Christian Torp-Pedersen, A John Camm, Noam N Butterfield, Garth Dickinson, Gregory N Beatch

Research output: Contribution to journal › Journal article › Research › peer-review

26 Citations (Scopus)

Abstract

Vernakalant is a novel, relatively atrial-selective antiarrhythmic drug. This analysis assessed the efficacy and safety of intravenous vernakalant for the rapid conversion of atrial fibrillation (AF) to sinus rhythm in patients with a history of ischemic heart disease (IHD).

Original language	English
Journal	International Journal of Cardiology
Volume	166
Issue number	1
Pages (from-to)	147-151
ISSN	0167-5273
DOIs	https://doi.org/10.1016/j.ijcard.2011.10.108
Publication status	Published - 2013
Externally published	Yes

Access to Document

10.1016/j.ijcard.2011.10.108

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

@article{5398980addf744b3b43758204ec1592a,

title = "Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease",

abstract = "Vernakalant is a novel, relatively atrial-selective antiarrhythmic drug. This analysis assessed the efficacy and safety of intravenous vernakalant for the rapid conversion of atrial fibrillation (AF) to sinus rhythm in patients with a history of ischemic heart disease (IHD).",

author = "Christian Torp-Pedersen and Camm, {A John} and Butterfield, {Noam N} and Garth Dickinson and Beatch, {Gregory N}",

year = "2013",

doi = "10.1016/j.ijcard.2011.10.108",

language = "English",

volume = "166",

pages = "147--151",

journal = "International Journal of Cardiology",

issn = "0167-5273",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Vernakalant

T2 - conversion of atrial fibrillation in patients with ischemic heart disease

AU - Torp-Pedersen, Christian

AU - Camm, A John

AU - Butterfield, Noam N

AU - Dickinson, Garth

AU - Beatch, Gregory N

PY - 2013

Y1 - 2013

N2 - Vernakalant is a novel, relatively atrial-selective antiarrhythmic drug. This analysis assessed the efficacy and safety of intravenous vernakalant for the rapid conversion of atrial fibrillation (AF) to sinus rhythm in patients with a history of ischemic heart disease (IHD).

AB - Vernakalant is a novel, relatively atrial-selective antiarrhythmic drug. This analysis assessed the efficacy and safety of intravenous vernakalant for the rapid conversion of atrial fibrillation (AF) to sinus rhythm in patients with a history of ischemic heart disease (IHD).

U2 - 10.1016/j.ijcard.2011.10.108

DO - 10.1016/j.ijcard.2011.10.108

M3 - Journal article

C2 - 22108512

SN - 0167-5273

VL - 166

SP - 147

EP - 151

JO - International Journal of Cardiology

JF - International Journal of Cardiology

IS - 1

ER -

Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease

Abstract

Access to Document

AUB Link

Fingerprint

Cite this